Mutational and expressional analysis of ERBB3 gene in common solid cancers

APMIS

Volumn 122, Issue 12, 2014, Pages 1207-1212

  Choi, Mi Ryoung ^a   An, Chang Hyeok ^a   Chung, Yeun Jun ^a   Choi, Youn Jin ^a   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Colon cancer; ERBB2; ERBB3; Expression; Gastric cancer; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 PROTEIN, HUMAN;

ARTICLE; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER TISSUE; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOMA; LIVER CELL CARCINOMA; MALE; MENINGIOMA; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; SARCOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL TUMOR; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; STOMACH TUMOR; TUMOR CELL LINE;

ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, ERBB-3; SEQUENCE ANALYSIS, DNA; STOMACH NEOPLASMS;

EID: 84922480459     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12286     Document Type: Article

References (25)

1. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
2. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
3. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
4. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
5. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66-77.
6. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
7. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999;19:6845-57.
8. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze. Proc Natl Acad Sci U S A 2010;107:7692-7.
9. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 2009;106:21608-13.
10. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003;11:495-505.
11. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
12. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
14. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
15. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol 2009;6:352-66.
16. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
17. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 2013;23:603-17.
18. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
19. Kim MS, Hur SY, Yoo NJ, Lee SH. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 2010;221:147-52.
20. Kim MS, Oh JE, Kim YR, Park SW, Kang MR, Kim SS, et al. Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J Pathol 2010;221:139-46.
21. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 2010;220:446-51.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
23. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009;114:263-75.
24. Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R, Lin KY, et al. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology 2011;53:504-16.
25. Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 2012;3:744-58.